The LBAs to Watch for at the 2026 ASCO Meeting

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting kicks off on May 29^th, 2026, in Chicago. This year’s theme is The Science and Practice of Translation: Improving Cancer Outcomes Worldwide, and over 200 presentations will serve to complement. Here, we’ve outlined some of the most anticipated late-breaking abstracts (LBAs) set to be presented during the meeting.

Breast Cancer

LBA1003 — Izalontamab Brengitecan vs Physician’s Choice of Chemotherapy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer: A Randomized Phase 3 Study

This study is evaluating the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren) for the treatment of patients with locally advanced or metastatic triple-negative breast cancer (TNBC). According to the official topline results, iza-bren successfully achieved statistically significant and clinically meaningful improvements in both of its dual primary end points of progression-free survival (PFS) and overall survival (OS) compared with physician's choice of chemotherapy.

Because traditional single-agent chemotherapy lines show low response rates and poor durability in later-line metastatic TNBC, the positive dual survival readout positions iza-bren to aggressively challenge the established treatment paradigm.

Presentation Details: June 2 at 10:45am CDT

LBA1007 — First-Line Camizestrant for Emergent ESR1 Mutations in Advanced Breast Cancer: Final Progression-Free Survival 2 From the Phase 3 SERENA-6 Trial

The pivotal phase 3 SERENA-6 trial (NCT04964934) established a new therapeutic paradigm in oncology by evaluating an early, circulating tumor DNA (ctDNA)-guided treatment intervention before radiographic progression.²The study investigated the clinical utility of switching from an aromatase inhibitor to the next-generation oral selective estrogen receptor degrader (SERD) camizestrant when an ESR1 mutation is detected in ctDNA. This LBA will focus on final PFS2 data.

This ASCO presentation follows a controversial April 30th Oncologic Drugs Advisory Committee (ODAC) meeting.³ The committee voted 6 to 3 against endorsing the clinical benefit of camizestrant in this setting. The central voting question was whether switching to camizestrant upon detecting an ESR1 mutation prior to radiographic progression demonstrated a clinically meaningful benefit for patients. The split vote reflects a profound philosophical divide between accepting a molecularly driven early intervention vs adhering to traditional radiographic-progression end points.

Presentation Details: June 2 at 11:57am CDT

LBA1006 — Giredestrant + Palbociclib vs Letrozole + Palbociclib as First-Line Therapy in Patients With Estrogen Receptor–Positive, HER2-Negative Locally Advanced or Metastatic Breast cCncer: Primary Analysis of the Phase 3 persevERA BC Trial

The primary analysis of the global phase 3 persevERA BC trial (NCT04546009) represents a major readout for next-generation oral SERDs the front-line setting.

Roche/Genentech, the sponsor, released topline findings from this 992-patient study. The trial did not meet its primary end point of achieving a statistically significant improvement in investigator-assessed PFS in the intent-to-treat population, marking a significant hurdle for the front-line use of oral SERDs in unselected, endocrine-sensitive metastatic populations.⁴

While the persevERA trial fell short of its primary benchmark in the front-line metastatic setting, it stands in stark contrast to giredestrant's notable victories elsewhere in the disease landscape. The data must be contextualized alongside parallel phase 3 successes in adjuvant and later-line settings.

Presentation Details: June 2 at 11:45am CDT

LBA503: Omission Of Completion Axillary Dissection In Patients With Breast Cancer and Sentinel Lymph Node Macrometastases: Overall Survival and Patient-Reported Arm Morbidity From the Randomized SENOMAC Trial

The SENOMAC trial (NCT02240472) randomized 2540 patients with clinically node-negative T1-T3 breast cancer and 1 or 2 sentinel lymph node macrometastases to completion axillary dissection versus sentinel lymph node biopsy alone. Results published in the New England Journal of Medicine in April 2024 demonstrated noninferior 5-year recurrence-free survival with omission of axillary dissection (89.7% vs 88.7%; HR, 0.89; 95% CI, 0.66-1.19; P <.001 for noninferiority), while arm morbidity was significantly worse with dissection versus biopsy alone (13% vs 4% reporting severe or very severe impairment; P <.0001).⁵ This ASCO 2026 presentation delivers the trial's primary end point of mature overall survival data alongside updated patient-reported outcomes.

Presentation Details: May 30 at 2:15pm CDT

Lung Cancer

LBA4 — Ivonescimab Plus Chemotherapy vs Tislelizumab Plus Chemotherapy in Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer: Overall Survival Results of the Phase 3 HARMONi-6 Trial

The phase 3 HARMONi-6 trial (NCT05840016) directly compares the first-in-class PD-1/VEGF bispecific antibody ivonescimab against a standard anti­–PD-1 inhibitor in the ifrst-line setting in patients with unresectable stage IIIB to IV advanced squamous non–small cell lung cancer (NSCLC).

Previously published data revealed a median PFS of 11.1 months with ivonescimab vs 6.9 months with tislelizumab (Tevimbra) and chemotherapy.⁶ This represents a 40% reduction in the risk of disease progression or death (HR, 0.60; P =.0001). The PFS benefit was consistently observed across all prespecified patient subgroubs, notably remaining effective regardless of PD-L1 expression. The ORR and DOR were also higher in the ivonescimab arm.

This abstract at ASCO will reveal OS data, offering confirmation of ivonescimab’s benefits over established backbone treatments in this patient population.

Presentation Details: May 31 at 2:47pm CDT

LBA3 — Event-Free Survival With Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial 

Selpercatinib (Retevmo) is an FDA-approved RET inhibitor for metastatic RET fusion–positive NSCLC based on LIBRETTO-001 (NCT03157128), with established systemic and central nervous system activity in advanced disease. In the adjuvant setting, the LIBRETTO-432 trial (NCT04819100) inquires into whether earlier RET targeting shifts long-term cure rates or primarily delays relapse in a potentially curative population.⁷

Presentation Details: May 31 at 2:13pm CDT

LBA8500 — Sunvozertinib Monotherapy vs Platinum-Based Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon20ins: Primary Analysis of a Multinational Phase 3 Randomized Study (WU-KONG28)

The FDA granted accelerated approval to sunvozertinib (Zegfrovy) for advanced NSCLC with an EGFR exon 20 insertion based on the 46% overall response rate (ORR) and 11.1-month duration of response (DOR) in the prior WU-KONG1B trial (NCT03974022).⁸ The phase 3 WU-KONG28 trial (NCT05668988) has reported superior PFS as well as ORR and DOR compared with doublet chemotherapy;⁹ the ASCO presentation will include full results from this trial and establish the utility of targeted therapy without chemotherapy as an option in the first line.

Presentation Details: May 29 at 1:00pm CDT

GI Cancers

LBA4000 — Efficacy and Safety Results from EMERALD-3: A Phase 3, Randomized Study of Tremelimumab Plus Durvalumab With or Without Lenvatinib Combined with Transarterial Chemoembolization in Patients With Embolization-Eligible Unresectable Hepatocellular Carcinoma

EMERALD-3 (NCT05301842) builds on the established STRIDE regimen of durvalumab (Imfinzi) plus tremelimumab (Imjudo), already FDA approved in advanced disease that has shown a significant 5-year OSbenefit (HR, 0.76) over sorafenib (Nexavar) in the HIMALAYA trial (NCT03298451).

The upcoming readout will define the magnitude of benefit and safety of multimodality treatment, specifically evaluating the added value of integrating locoregional therapy and tyrosine kinase inhibitor intensification with lenvatinib (Lenvima).¹⁰

Presentation Details: June 1 at 9:45am CDT

GU Cancers

LBA4511 — Durvalumab Monotherapy vs Active Monitoring for Resected Primary Renal Cell Carcinoma in RAMPART: An International, Phase 3, Randomized Controlled Trial

The phase 3 RAMPART trial (NCT03288532) is evaluating adjuvant durvalumab as monotherapy or combined with tremelimumab vs active monitoring in patients with resected primary renal cell carcinoma (RCC).¹¹ Data from the single-agent durvalumab arm are being presented at ASCO. Previously reported 3-year data for the combination arm showed a disease-free survival rate in the intention-to-treat population of 81% vs 73% with active monitoring (HR, 0.65; 95% CI, 0.45-0.93; P =0094). Regarding single-agent checkpoint inhibition in a similar setting, the KEYNOTE-564 trial led to the FDA approval of adjuvant pembrolizumab (Keytruda) for certain patients with RCC. There are key differences between RAMPART and KEYNOTE-564 which will likely be highlighted during the ASCO presentation.

Presentation Details: May 30 at 8:36am CDT

LBA1 — Final Analysis of PROTEUS, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Perioperative Apalutamide Plus ADT vs ADT With Radical Prostatectomy in Men With High-Risk Localized Prostate Cancer

The phase 3 PROTEUS trial (NCT03767244) is evaluating perioperative apalutamide (Erleada) plus androgen deprivation therapy (ADT)—given for 6 months before and after radical prostatectomy—vs placebo plus ADT in men with high-risk localized prostate cancer, where there are high recurrence rates following surgery. The dual primary end points are pathologic complete response rate and metastasis-free survival, with overall survival as a key secondary end point. This final analysis represents the first primary efficacy readout from PROTEUS and could support a regulatory submission expanding apalutamide's label into the localized disease setting. Apalutamide is currently FDA approved for nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Presentation Details: May 31 at 1:05pm CDT

LBA5007 — TALAPRO-3: Talazoparib Plus Enzalutamide Compared With Placebo Plus Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer Harboring Homologous Recombination Repair Gene Alterations

The phase 3 TALAPRO-3 trial (NCT04821622) evaluates talazoparib (Talzenna) plus enzalutamide (Xtandi) versus placebo plus enzalutamide in 599 patients with HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) across 27 countries. Talazoparib plus enzalutamide is already FDA approved for HRR-mutated mCRPC based on TALAPRO-2 data (radiographic PFS [rPFS]; HR, 0.63).¹² Earlier this year, it was reported that TALAPRO-3 met its primary end point of rPFS, with a hazard ratio exceeding the prespecified target of 0.63 and the majority of patients progression-free at the time of interim analysis.¹³ Efficacy benefit was consistent across both BRCA and non-BRCA HRR gene alterations. This ASCO 2026 presentation will provide the first full efficacy and safety data readout, potentially supporting a regulatory submission to expand the combination into the earlier mCSPC setting.

Presentation Details: May 30 at 5:12pm CDT

Lymphoma

LBA7000 — frontMIND: Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma 

The CD19-targeting monoclonal antibody tafasitamab (Monjuvi) is already approved with lenalidomide (Revlimid) in the relapsed/refractory setting based on the L-MIND study (NCT02399085), but frontline escalation has historically been challenging in this disease. Forthcoming data from frontMIND (NCT04824092) are expected to clarify the benefit of the combination plus an R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, prednisone) backbone in the frontline setting, with a supplemental biologics license application expected for filing in the first half of 2026.¹⁴

Presentation Details: May 30 at 3:00pm CDT

Multiple Myeloma

LBA7506 — Mezigdomide, Carfilzomib, and Dexamethasone (MexiKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 SUCCESSOR-2 Trial

The SUCCESSOR-2 trial (NCT05552976) reported improved progression-free survival with the addition of mezigdomide to carfilzomib (Kyprolis) and dexamethasone, making this the first positive phase 3 trial of the CELMoD (cereblon E3 ligase modulator).¹⁵ At ASCO, the full efficacy and safety results will be presented for the first time, revealing the degree of benefit this investigational agent offers. Among other CELMoD trials, this stands to update the standard of care in patients who have disease refractory to lenalidomide (Revlimid).

The trial implemented a first-of-its-kind seamless phase 2/3 design to assess multiple dose levels of mezigdomide as a dose optimization strategy favored by the FDA, before proceeding to randomization vs standard of care.

Presentation Details: May 29 at 4:45pm CDT

Sarcoma

LBA2 — SARC041: A Phase 3 Randomized Double-Blind Study of Abemaciclib vs Placebo in Patients with Advanced Dedifferentiated Liposarcoma

CDK4/6 inhibition, familiar to breast cancer treatment, is a developing strategy in dedifferentiated liposarcoma. The phase 3 SARC041 trial (NCT04967521) randomly assigned patients 1:1 to 200 mg abemaciclib (Verzenio) twice daily vs placebo with a primary end point of PFS.¹⁶ The study enabled rapid crossover to abemaciclib from the placebo group based on radiologic review. A single-arm phase 2 study (NCT02846987) of this agent previously met its primary end point of at least 60% PFS rate at 12 weeks.¹⁷

Presentation Details: May 31 at 1:39pm CDT

REFERENCES

1. SystImmune and Bristol Myers Squibb highlight positive phase III interim topline results for izalontamab brengitecan (Iza-bren) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer. News release. February 26, 2026. Accessed May 20, 2026. https://tinyurl.com/4y5cxjvb

2. Bidard FC, Mayer EL, Park YH, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1. PMID: 40454637.

3. April 30, 2026 Meeting of the Oncologic Drugs Advisory Committee (ODAC). US FDA. Accessed May 20, 2026. https://tinyurl.com/yk8k3yws

4. Roche provides update on phase III persevERA study in ER-positive advanced breast cancer. News release. Roche. March 8, 2026. Accessed May 20, 2026. https://tinyurl.com/5d46urx4

5. de Boniface J, Filtenborg Tvedskov T, Rydén L, et al. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. PMID: 38598571.

6. Chen Z, Yang F, Jiang Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025 Nov 1;406(10515):2078-2088. doi: 10.1016/S0140-6736(25)01848-3. Epub 2025 Oct 19. Erratum in: Lancet. 2026 Jan 17;407(10525):226. doi: 10.1016/S0140-6736(26)00048-6. PMID: 41125109.

7. Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer. News release. Eli Lilly and Company. February 16, 2026. Accessed May 8, 2026. https://tinyurl.com/3f8fw953

8. FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. FDA. July 2, 2025. Accessed May 15, 2026. https://tinyurl.com/52k2z4z6

9. Dizal announces positive topline phase 3 results from WU-KONG28 study: evaluating oral, once-daily ZEGFROVY® (sunvozertinib) vs. platinum-containing chemo doublet in first-line non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins). News release. Dizal. March 23, 2025. Accessed May 15, 2026. https://tinyurl.com/hbxjj9xf

10. Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 phase III trial. News release. AstraZeneca. April 2, 2026. Accessed May 8, 2026. https://tinyurl.com/3mcvnk93

11. Oza B, Frangou E, Smith B, et al. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials. 2021 Sep;108:106482. doi: 10.1016/j.cct.2021.106482. Epub 2021 Sep 16. PMID: 34538402; PMCID: PMC8520913.

12. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):447-460. doi: 10.1016/S0140-6736(25)00684-1. Epub 2025 Jul 16. PMID: 40683290.

13. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer. News release. March 19, 2026. Accessed March 19, 2026. https://tinyurl.com/539e6k6m

14. Incyte announces positive topline results from pivotal study of tafasitamab (Monjuvi/Minjuvi) as a first-line treatment for diffuse large B-cell lymphoma. News release. Incyte. January 5, 2026. Accessed May 8, 2026. https://tinyurl.com/3y9mepeu

15. Bristol Myers Squibb announces positive phase 3 results from the SUCCESSOR-2 study of oral mezigdomide in relapsed or refractory multiple myeloma. News release. Bristol Myers Squibb. March 9, 2026. Accessed March 9, 2026. https://tinyurl.com/mubr9veh

16. SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma. ClinicalTrials.gov. Updated December 6, 2024. Accessed May 15, 2026. https://clinicaltrials.gov/study/NCT04967521

17. Dickson MA, Koff A, D’Angelo SP, et al. Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol. 2019;37(suppl 15):11004. doi:10.1200/JCO.2019.37.15_suppl.11004